Angka Kejadian dan Faktor yang Memengaruhi Potensi Interaksi Obat dengan Obat pada Pasien Leukemia Akut Anak yang Menjalani Rawat Inap

Background. Risk of potential drug-drug interactions (pDDIs) in patients with acute leukemia due to administration of multidrug therapy is quite high, and studies in pediatric patients have not been done before. Objectives. To determine the incidence and factors that affect pDDIs. Methods. A cross-sectional study design with the subjects of pediatric inpatient with acute leukemia in RSCM from January to December 2014. Data obtained through the electronic prescription retrospectively. PDDIs were identified by Micromedex Drug Reax® software. Results. Ninety six pediatric inpatient fulfilled the criteria. PDDIs were identified in 41,6% samples with the severity of contraindications (4,70%), major (60,70%), and moderate (34,60%). The most frequent pDDIs involved dexamethasone and fluconazole that potentially increased glucocorticoid exposure. There are significant differences in the factor of age (p=0.037), length of stay (LOS) (p=0.000), and the mean number of medications (p=0.000), while comorbidity showed no significant difference (p=0.082). Conclusions. Incidence rates of pDDIs in pediatric inpatient with acute leukemia in RSCM is 41.6%. Age, LOS, and the mean number of medications have significant differences on the incidence of pDDIs with OR 1.8 for the patients aged >7 years, 6.3 for the patients with LOS >7 days, and 5.3 of the patients with >4 drugs given per day.